Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Local treatments | Local multimodal treatments (thoracic surgery/radiotherapy + brain surgery/radiotherapy) |
| |
| Systemic treatment | Chemoimmunotherapy combination |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Standard treatments / multiple strategies | Other | Standard treatments / multiple strategies |
|
| Measure | Description | Time Frame |
|---|---|---|
| Progression free survival (PFS) | Time from random assignment in a clinical trial to disease progression or death from any cause | Once, at progression or death from any cause |
| Measure | Description | Time Frame |
|---|---|---|
| PFS from the date of the next treatment to disease progression or death from any cause (PFS2) | PFS from the date of the next treatment to disease progression or death from any cause | Once, at progression or death from any cause |
| Overall survival (OS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Patient with NSCLC treated at CHU Bordeaux and Bergonié Institute
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Bordeaux | Bordeaux | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D001932 | Brain Neoplasms |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive
| Once, death from any cause or lost of follow-up |
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |